Physician profile
Prabhat Singh
NPI 1780972133
$921.87
in general payments reported to CMS, 2019-2025
16 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.19 · 2021: $67.42 · 2022: $65.09 · 2023: $278 · 2024: $188 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.17 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $192.27 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $149.60 | 2019-2025 | |
| Outset Medical INC | $109.73 | 2023 | |
| Amgen INC. | $94.72 | 2024-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $60.00 | 2023 | Benlysta |
| Novo Nordisk INC | $52.08 | 2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $38.29 | 2023 | Lupkynis |
| Horizon Therapeutics Plc | $34.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.92 | 2021 | |
| Medtronic, INC. | $27.92 | 2025 | Symplicity G3 |
| Janssen Biotech, INC. | $27.01 | 2023 | Stelara |
| Travere Therapeutics, INC. | $26.05 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $24.46 | 2022 | |
| Calliditas Therapeutics US INC. | $19.76 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $17.98 | 2024 | Jynarque |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $15.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhat Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.